Blood Glucose Monitoring Test Strips Improved
|
By LabMedica International staff writers Posted on 24 Nov 2009 |
A new and improved blood glucose monitoring test strip has been launched.
The Assure Pro blood glucose monitoring system is designed for long-term care and multiresident use settings. Feature loaded, the Assure Pro meter helps facilities meet state regulatory standards and provide better resident care. The strips require 50% less blood, reducing the sample size from 1 µL to only 0.5 µL. All Assure blood glucose-monitoring systems utilize glucose oxidase (GO) strip chemistry, which is not affected by interferences that cause testing errors in other common test strips.
Assure Blood Glucose Meters are backed by the Assure Brilliance program--a comprehensive service program for diabetes management in long-term care (LTC). Assure Brilliance provides customer service, on-site training, Quality Assurance/Quality Control (QA/QC) guidance, diabetes F-Tag advice for LTC, a quarterly newsletter, online CE programs, and more to help facilities manage complex diabetes care in their facilities.
Arkray Inc. (Edina, MN, USA), a manufacturer of diabetes self-monitoring systems, launched the new and improved Blood Glucose Monitoring Test Strip. The company manufactures and distributes cost-effective products that are simple, convenient, and easy-to-use, including blood glucose meters, test strips, safety lancets, and urine chemistry.
Related Links:
Arkray Inc.
The Assure Pro blood glucose monitoring system is designed for long-term care and multiresident use settings. Feature loaded, the Assure Pro meter helps facilities meet state regulatory standards and provide better resident care. The strips require 50% less blood, reducing the sample size from 1 µL to only 0.5 µL. All Assure blood glucose-monitoring systems utilize glucose oxidase (GO) strip chemistry, which is not affected by interferences that cause testing errors in other common test strips.
Assure Blood Glucose Meters are backed by the Assure Brilliance program--a comprehensive service program for diabetes management in long-term care (LTC). Assure Brilliance provides customer service, on-site training, Quality Assurance/Quality Control (QA/QC) guidance, diabetes F-Tag advice for LTC, a quarterly newsletter, online CE programs, and more to help facilities manage complex diabetes care in their facilities.
Arkray Inc. (Edina, MN, USA), a manufacturer of diabetes self-monitoring systems, launched the new and improved Blood Glucose Monitoring Test Strip. The company manufactures and distributes cost-effective products that are simple, convenient, and easy-to-use, including blood glucose meters, test strips, safety lancets, and urine chemistry.
Related Links:
Arkray Inc.
Latest Clinical Chem. News
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
- Blood Test Tracks Transplant Health Using Donor DNA
- New Blood Test Index Offers Earlier Detection of Liver Scarring
- Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Channels
Molecular Diagnostics
view channel
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read more
Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
Accurate identification of breast cancer patients at risk of relapse after pre-surgery treatment is central to guiding adjuvant decisions, particularly in aggressive disease. Circulating fragments of tumor... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read more
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more




.jpg)



